ASTC - Astrotech shares jump as subsidiary inks deal to study BreathTest-1000 in COVID-19 patients

Astrotech (ASTC) company BreathTech has signed an Investigator-Initiated Study Agreement with the Cleveland Clinic Foundation for the use of its BreathTest-1000 to compare exhaled breath from individuals who have tested positive on a COVID-19 polymerase chain reaction ((PCR)) test with that from subjects who have had a negative COVID-19 PCR test.Astrotech shares up nearly 14% during premarket trading.The goal of the pilot study will be to analyze different volatile organic compounds ((VOCs)) from the breath to evaluate the correlation with different disease states.The data that will be collected as part of the pilot study will be used by BreathTech to develop and refine its detection algorithms.Favorable results may require confirmation in a subsequent larger study, the company said.

For further details see:

Astrotech shares jump as subsidiary inks deal to study BreathTest-1000 in COVID-19 patients